Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for a Single, Small Hepatocellular Carcinoma in Liver Transplant Candidates

被引:3
作者
Wu, Xiao [1 ]
Heller, Michael [1 ]
Kwong, Allison [3 ]
Fidelman, Nicholas [1 ]
Mehta, Neil [2 ]
机构
[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Gen Hepatol & Liver Transplantat, 513 Parnassus Ave,Room S-357, San Francisco, CA 94143 USA
[3] Stanford Univ, Dept Gastroenterol & Hepatol, San Francisco, CA USA
关键词
TRANSARTERIAL CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION; TRENDS; RESECTION; OUTCOMES; SCORE; Y-90;
D O I
10.1016/j.jvir.2023.02.016
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To assess the cost effectiveness of 3 main locoregional therapies (LRTs) (transarterial chemoembolization [TACE], transarterial radioembolization [TARE], and percutaneous ablation) as bridging therapy.Materials and Methods: A cost-effectiveness analysis was performed comparing the 3 LRTs for patients with a single hepatocellular carcinoma (HCC) with a diameter of 3 cm or less over a 5-year time horizon from a payer's perspective. The clinical courses, including transplantation, decompensation resulting in delisting, and the need for a second LRT, were based on data from the United Network for Organ Sharing (2016-2019). Costs and effectiveness were measured in U.S. dollars and quality-adjusted life-years, respectively. Probabilistic and deterministic sensitivity analyses were performed. Results: A total of 2,594, 1,576, and 903 patients underwent TACE, ablation, and TARE, respectively. Ablation was the dominant strategy, with the lowest expected cost and highest effectiveness. The probabilistic sensitivity analysis demon-strated that ablation was the most cost-effective strategy in 93.9% of simulations. A subgroup analysis was performed for different wait times, with ablation remaining the most cost-effective strategy. The sensitivity analysis showed that ablation was most effective if the risk of waitlist dropout was less than 2.00% and the rate of transplantation was more than 15.1% quarterly. TARE was most effective if the risk of dropout was less than 1.19% and the rate of transplantation was more than 24.0%. TACE was most effective if the risk of dropout was less than 1.01% and the rate of transplantation was more than 45.7%. Ablation remained the most cost-effective modality until its procedural cost was more than $34,843.Conclusions: Ablation is the most cost-effective bridging strategy for patients with a single, small (& LE;3 cm) HCC prior to liver transplantation. The conclusion remained robust in multiple sensitivity analyses.
引用
收藏
页码:1237 / 1246.e3
页数:13
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of interventional liver-directed therapies for downstaging of HCC before liver transplant
    Wu, Xiao
    Kwong, Allison
    Heller, Michael
    Lokken, R. Peter
    Fidelman, Nicholas
    Mehta, Neil
    LIVER TRANSPLANTATION, 2024, 30 (02) : 151 - 159
  • [2] New Insights on Liver-Directed Therapies in Hepatocellular Carcinoma
    Dalzell, Christina G.
    Taylor, Amy C.
    White, Sarah B.
    CANCERS, 2023, 15 (24)
  • [3] Liver-directed therapy for hepatocellular carcinoma
    O'Leary, Cathal
    Mahler, Mary
    Soulen, Michael C.
    CHINESE CLINICAL ONCOLOGY, 2021, 10 (01)
  • [4] Liver-directed therapy for hepatocellular carcinoma
    Narsinh, Kazim H.
    Duncan, David P.
    Newton, Isabel G.
    Minocha, Jeet
    Rose, Steven C.
    ABDOMINAL RADIOLOGY, 2018, 43 (01) : 203 - 217
  • [5] Liver-directed therapy for hepatocellular carcinoma
    Kazim H. Narsinh
    David P. Duncan
    Isabel G. Newton
    Jeet Minocha
    Steven C. Rose
    Abdominal Radiology, 2018, 43 : 203 - 217
  • [6] Longitudinal analysis of liver transplant candidates for hepatocellular carcinoma in a single center
    Ho, Cheng-Maw
    Lee, Po-Huang
    Cheng, Hou-Ying
    Hsaio, Chih-Yang
    Wu, Yao-Ming
    Ho, Ming-Chih
    Hu, Rey-Heng
    LANGENBECKS ARCHIVES OF SURGERY, 2024, 409 (01)
  • [7] Liver-Directed and Systemic Therapy Options for Hepatocellular Carcinoma
    Agarwal, Rajiv
    Matsuoka, Lea K.
    Brown, Daniel B.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (5.5):
  • [8] Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC)
    Viveiros, Pedro
    Riaz, Ahsun
    Lewandowski, Robert J.
    Mahalingam, Devalingam
    CANCERS, 2019, 11 (08)
  • [9] Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis
    Patel, Mikin V.
    Davies, Heather
    Williams, Abimbola O.
    Bromilow, Tom
    Baker, Hannah
    Mealing, Stuart
    Holmes, Hayden
    Anderson, Nicholas
    Ahmed, Osman
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1061 - 1071
  • [10] Analysis of liver-directed therapies in US cancer patients
    Alese, O. B.
    Kim, S.
    Chen, Z.
    Ramalingam, S. S.
    Owonikoko, T. K.
    El-Rayes, B. F.
    CURRENT ONCOLOGY, 2015, 22 (06) : E457 - E461